YOLFTbeta
Pliant Therapeutics Inc

Pliant Therapeutics Inc

PLRX · NASDAQ · Healthcare / Biotechnology

0.697USD-0.04 (-5.81%)

Price History

Full chart

Market Stats

Previous Close0.74
Open0.74
Day Range0.69 – 0.754
52-Week Range1.02 – 1.95
Volume877.13K
Market Cap66.88M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.51
Dividend Yield0.00%
Beta1.28
50-Day Avg1.10
200-Day Avg1.20

About

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Keith Lamont Cummings M.B.A., M.D.
  • Employees49
  • Headquarters331 Oyster Point Boulevard, South San Francisco, CA, United States, 94080, USA
  • Websitehttps://pliantrx.com

Leadership

  • Dr. Keith Lamont Cummings M.B.A., M.D.Chief Financial Officer · b. 1977
  • Ms. Minnie KuoChief Operating Officer · b. 1981
  • Dr. Rik Derynck Ph.D.Scientific Founder & Member of Scientific Advisory Board
  • Mr. Dean Sheppard M.D.Scientific Founder & Member of Scientific Advisory Board
  • Ms. Lily CheungChief Human Resources Officer · b. 1973
  • Dr. Tim Machajewski Ph.D.Senior VP & Head of Research
  • Mr. Scott PetersSenior Vice President of Finance
  • Mr. Daniel ParkSenior Vice President of Development Operations

Financials

Income Statement

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-057.05M41.82M7.57M9.69M1.58M00
Growth (%)----26.70%-81.89%+27.91%-83.69%-100.00%-
Cost of Revenue-666.00K--3.20M3.68M1.84M2.13M1.70M
Gross Profit--666.00K57.05M41.82M7.57M9.69M1.58M-2.13M-1.70M
Gross Margin--100.00%100.00%100.00%100.00%100.00%--
Operating Expense-30.25M58.28M83.46M27.56M136.88M185.72M226.24M148.38M
Operating Income-18.35M-30.91M-1.23M-41.65M-19.99M-127.20M-184.15M-228.37M-150.07M
Operating Margin---2.16%-99.59%-263.95%-1313.37%-11654.75%--
EBITDA-18.06M-30.25M-118.00K-40.34M-18.45M-118.85M-158.23M-205.16M-145.09M
EBITDA Margin---0.21%-96.46%-243.67%-1227.15%-10014.43%--
Net Income-20.62M-30.28M-631.00K-39.74M-17.91M-123.32M-161.34M-210.30M-149.34M
Net Income Margin---1.11%-95.05%-236.49%-1273.32%-10211.14%--
R&D14.53M24.41M47.35M66.19M77.55M96.94M127.80M169.31M109.16M
R&D as % of Total Revenue--83.00%158.29%1024.15%1000.89%8088.42%--
Interest Expense00216.00K366.00K272.00K791.00K1.27M3.02M2.56M
Interest Expense % of Total Revenue--0.38%0.88%3.59%8.17%80.19%--

Balance Sheet

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets6.55M66.53M119.06M295.53M221.22M350.61M512.15M396.95M225.23M
Total Liabilities3.19M67.41M119.50M12.46M22.16M37.27M38.58M92.87M44.02M
Total Equity3.35M-882.00K-435.00K283.06M199.06M313.34M473.58M304.08M181.21M
Cash4.25M60.95M85.81M50.88M51.66M33.69M63.23M71.19M45.45M
Total Debt-525.00K444.00K283.00K7.19M15.81M11.37M60.19M29.11M
Net Debt-4.25M-60.42M-85.36M-50.88M-44.47M-17.87M-51.86M-11.00M-16.34M

Cash Flow

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-16.92M-28.33M-2.75M-37.27M-75.44M-94.63M-116.36M-155.50M-128.34M
Investing Cash Flow-1.41M-2.32M-17.93M-210.87M73.70M-150.20M-127.01M140.34M134.29M
Financing Cash Flow20.01M87.35M45.54M213.21M2.53M226.85M274.40M23.12M-31.70M
Capital Expenditure1.41M2.32M964.00K1.53M1.95M1.76M921.00K3.85M374.00K
Free Cash Flow-18.33M-30.65M-3.71M-38.80M-77.40M-96.39M-117.28M-159.35M-128.71M
FCF to OCF108.30%108.20%135.05%104.11%102.59%101.86%100.79%102.47%100.29%

Earnings

Report DateJul 17, 2019Jun 3, 2020Aug 11, 2020Nov 10, 2020Mar 16, 2021May 10, 2021Aug 9, 2021Nov 9, 2021Feb 28, 2022May 9, 2022Aug 8, 2022Nov 8, 2022Mar 9, 2023May 9, 2023Aug 9, 2023Nov 9, 2023Feb 27, 2024May 6, 2024Aug 7, 2024Nov 7, 2024Feb 25, 2025May 8, 2025Aug 7, 2025Nov 6, 2025Mar 3, 2026May 11, 2026Aug 11, 2026Nov 5, 2026
EPS Estimate0.00--0.68-0.60-0.71-0.60-0.67-0.69-0.76-0.74-0.81-0.74-0.70-0.67-0.69-0.77-0.81-0.77-0.85-0.98-0.96-0.75-0.62-0.52-0.42-0.36-0.33-0.37
EPS Actual-0.21-0.20-1.39-0.47-0.54-0.64-0.64-0.75-0.68-0.78-0.82-0.65-0.72-0.67-0.70-0.70-0.69-0.78-0.92-0.95-0.82-0.92-0.71-0.43-0.35-0.32-0.36-
Surprise---104.41%21.67%23.94%-6.67%4.48%-8.70%10.53%-5.41%-1.23%12.16%-2.86%0.00%-1.45%9.09%14.81%-1.30%-8.24%3.06%14.15%-22.67%-14.52%17.31%14.97%11.11%-9.09%-
Timing-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap66.88M
Enterprise Value-60.01M
Trailing P/E0.00
Forward P/E0.00
Price / Sales3071.82
Price / Book0.47
EPS-1.51
Book Value2.37
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-89.87M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-50.29%
Return on Assets-23.27%
Shares Outstanding61.92M
Shares Float55.03M
Beta1.28
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 13 analystsTarget 2.00
  • Strong Buy
    1
  • Buy
    1
  • Hold
    11

Ownership Breakdown

Institutions
79.24%
Insiders
2.23%
Retail / Other
18.53%

Top Institutional Holders

  • TANG CAPITAL MANAGEMENT LLC
    6.14M9.92%
  • ADAR1 Capital Management LLC
    2.59M4.17%
  • Acadian Asset Management LLC
    2.42M3.90%
  • Vanguard Capital Management, LLC
    2.34M3.78%
  • Two Sigma Investments LLC
    2.26M3.65%
  • Citadel Advisors Llc
    2.14M3.46%
  • Monaco Asset Management
    1.94M3.13%
  • Renaissance Technologies Corp
    1.85M2.99%
  • Lynx1 Capital Management, LP
    1.80M2.90%
  • Woodline Partners LP
    1.67M2.69%
  • BML Capital Management LLC
    1.55M2.50%
  • Prosight Management, LP
    1.37M2.21%
  • Peapod Lane Capital LLC
    1.31M2.11%
  • BlackRock Inc
    1.10M1.77%
  • UBS Group AG
    1.06M1.71%
  • Marshall Wace Asset Management Ltd
    995.97K1.61%
  • Eversept Partners, LP
    891.42K1.44%
  • JPMorgan Chase & Co
    861.82K1.39%
  • Redmile Group, LLC
    772.13K1.25%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.75M2.82%